Pancreas Transplantation
Methodology & AI Transparency ⓘ
Pancreas Transplantation Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: The pancreas is a gland behind your stomach and in front of your spine.
- 2 Real-world patient consensus: Clinical coding for Pancreas Transplantation uses ICD-10 E10.4 across Diabetes & Glucose specialty care.
- 3 Typical cash cost range: Primary evaluation for Pancreas Transplantation incorporates fasting insulin/C-peptide quantification [Pancreas Transplantation E10.4] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Pancreas Transplantation: maintaining CGM Time-in-Range (70–140 in Pancreas Transplantation (E10.4: mg/dL)) within > 85% (E10.4).
Ask our AI Specialists anything about Pancreas Transplantation
What Is Pancreas Transplantation?
The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. A pancreas transplant is surgery to place a healthy pancreas from a donor into a person with a diseased pancreas. It is mostly done for people with severe type 1 diabetes . It can allow them to give up insulin shots. An experimental procedure called islet cell transplantation transplants only the parts of the pancreas that make insulin. People who have transplants must take drugs to keep their body from rejecting the new pancreas for the rest of their lives.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Pancreas Transplantation (code E10.4) is impaired incretin GLP-1/GIP in Pancreas Transplantation (E10.4: signaling), Cross-referenced with NIH MeSH (Pancreas Transplantation), which Type 1 & Type 2 Diabetes clinicians address while surveilling CGM Time-in-Range (70–140 in Pancreas Transplantation (E10.4: mg/dL)) (> 85% (E10.4)).
Common Symptoms & Clinical Signs
- • Presentation of Pancreas Transplantation (E10.4): increased thirst [Pancreas Transplantation E10.4]
- • Secondary Pancreas Transplantation clinical sign: postprandial afternoon energy in Pancreas Transplantation (E10.4: crashes and carbohydrate)
- • Symptom flares in Pancreas Transplantation correlating with CGM Time-in-Range (70–140 in Pancreas Transplantation (E10.4: mg/dL)) deviation outside > 85% (E10.4)
- • Functional diabetes & glucose impact requiring fasting insulin/C-peptide quantification [Pancreas Transplantation E10.4] evaluation (E10.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pancreas Transplantation Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E10.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Pancreas Transplantation (E10.4: mg/dL)) | > 85% (E10.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Pancreas Transplantation E10.4] | 4.8% – 5.6% (< 6.5% clinical target) (E10.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Pancreas Transplantation E10.4] | 75 – 95 mg/dL (E10.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pancreas Transplantation
Treatment selection for Pancreas Transplantation depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pancreas Transplantation)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Quality of life outcomes with a new sustained‑release pregabalin in a phase 3: What a 296-Participant Study Found Once-daily SR pregabalin (YHD1119) achieved QoL outcomes comparable to twice-daily IR pregabalin across general health status, sleep interference, and global impressions over 12 weeks. Current medical research and opinion • 2026-07-15 • Phase III Randomized Trial | N = 296 | 93/100 | PMID 42622433 ↗ |
| New Insights on Effect of Moderate and Severe Persistent high blood sugar on Outcomes in Patients: What a 1,000-Participant Study Found Persistent high blood sugar, either moderate or severe, increased the risk of death or disability in nondiabetic patients with intracerebral hemorrhage. Stroke • 2022-04-15 • Phase III Randomized Trial | N = 1,000 | 90/100 | PMID 34844422 ↗ |
| New Insights on Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral: What a 227-Participant Study Found Overall results of electrophysiological measurements were inconclusive, with significant improvement in individual measurements limited primarily to the ulnar and median nerves. Diabetes • 2024-05-01 • Phase III Randomized Trial | N = 227 | 88/100 | PMID 38320260 ↗ |
| Can This Approach Help? Inside the Latest Research on Intravitreal conbercept for diabetic macular oedema: 2-year results from a The use of a conbercept PRN intravitreal injection regimen improved the BCVA of patients with DME, and its efficacy was better than that of laser photocoagulations, and the same efficacy was observed when the eyes treated with... The British journal of ophthalmology • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34001667 ↗ |
Pancreas Transplantation Patient Community & “People Like Me” Threads
Filter Pancreas Transplantation community threads and patient logs by age, biological sex, dosage, and treatment duration.